In general, reducing thrombotic risk by managing cardiovascular risk factors, namely obesity, diabetes mellitus, hypertension, hyperlipidaemia, and smoking through lifestyle modifications, regular exercise, and medical therapies, despite the absence of clinical trials showing their benefits, is still considered to be important in managing all patients with aPL and APS. The gene discussed is FASLG; the disease is hyperlipidemia.